|
|
 |
|
Viewing report
|
|
|
|
Dyslipidemia Therapeutics - Global Strategic Business Report
Global Industry Analysts, Inc., April 2010, Pages: 429
This report analyzes the worldwide markets for Dyslipidemia Therapeutics in US$ Million by the following segments - Statins, and Non-Statins.
The report provides separate comprehensive analytics for US, Japan, Europe, and Rest of World.
Annual estimates and forecasts are provided for each region for the period 2006 through 2015.
The report profiles 41 companies including many key and niche players worldwide such as Abbott Laboratories, AstraZeneca, PLC, GlaxoSmithKline, Inc., Merck & Co., Inc., Mylan, Inc., Novartis AG, Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.
Market data and analytics are derived from primary and secondary research.
Company profiles are mostly extracted from URL research and reported select online sources.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.
For information on site licence pricing please click on Enquire before buying
Customers who bought this item also bought
Bladder Cancer Therapeutics - Global Strategic Business Report
Lipid Regulators - Global Strategic Business Report
Bipolar Disorder - Global Strategic Business Report
Anti-Infectives - Global Strategic Business Report
Multiple Sclerosis Therapeutics - Global Strategic Business Report
Rheumatoid Arthritis Therapeutics - Global Strategic Business Report
Lymphoma Therapeutics - Global Strategic Business Report
Intravenous (IV) Iron Drugs - Global Strategic Business Report
Antibacterial Drugs - Global Strategic Business Report
Prostate Cancer Therapeutics - Global Strategic Business Report
|
|
|
|
